Indian pharma stocks fell for the third consecutive session amid concerns of potential US tariffs on pharmaceutical imports.

By Bharath Rajeswaran (Reuters) -Indian equity benchmarks advanced on Thursday, driven by gains in heavyweight financials, ...

The Board of Directors, in a meeting held on 25 March 2025, declared an interim dividend of Rs 25 per equity share on a face ...

India's pharmaceutical industry is urging its government to negotiate with Washington from a “position of power” on tariffs ...

Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan ...

The move follows the approval from the National Company Law Tribunal (NCLT), New Delhi Bench. With this consolidation, the ...

In an expert call, the brokerage addressed possibilities of pass-through of tariffs to consumers, and the feasibility of ...

Given the extent of India’s pharma exports to US, this has created a certain bit of uncertainty in the market. Trump said the US would impose tariffs on autos, pharmaceuticals and aluminum in ...

Among the 30 Sensex stocks, Infosys fell the most upon opening by 0.54 per cent, trading at ₹ 1,594.95. This was followed by ...

As the April 2 deadline for Trump’s reciprocal tariffs approaches, Indian markets brace for potential disruptions. While ...

Experts underestimated Trump's seriousness on tariffs; Indian auto and pharma sectors brace for impact, while steel remains ...